Beactica Therapeutics

Beactica Therapeutics AB is a specialized drug discovery company that leverages its proprietary methods to evaluate molecular interactions for the development of new therapeutic approaches. In addition to advancing its own drug discovery programs, Beactica also utilizes its proprietary discovery platform to offer partnerships in fragment-based lead generation. Building on its foundation since its establishment in 2006, Beactica has earned a reputation as a leader in SPR biosensor-based small molecule drug discovery at Uppsala University. Beactica is the chosen discovery partner for companies like J&J, Boehringer Ingelheim, Almac, and Medivir, aiming to advance priority drug discovery initiatives. These companies benefit from Beactica’s unique expertise and proprietary technologies to drive projects addressing needs related to fragment-based lead generation, orthosteric inhibitor identification, interaction kinetics optimization, and complex mechanisms of action.